Skip to main content

Advertisement

Table 2 Investigational course, P-value representing a test for difference

From: Characteristics and outcome in patients with non-specific symptoms and signs of cancer referred to a fast track cancer patient pathway; a retrospective cohort study

  All Cancera No-cancera P-value
  N = 825 N = 138 N = 687  
Length of investigational course in days median (IQR)b 9 (1–15) 10 (1–16) 9 (1–15) 0.699
Number of visits at the NSSC-CPP median (IQR) 2 (1–2) 2 (1–2) 2 (1–2) 0.960
Diagnostic imaging used during or prior to the investigational course %(n)
 CT 39.0 (322) 42.8 (59) 38.3 (263) 0.326
 FDG-PET/CT 30.4 (251) 38.4 (53) 28.8 (198) 0.026
 Ultrasound 16.0 (132) 10.9 (15) 17.0 (117) 0.072
 MRI 5.3 (44) 2.9 (4) 5.8 (40) 0.163
 No advanced imaging 23.3 (192) 22.5 (31) 23.4 (161) 0.805
Pathological examinations and endoscopies performed during investigational course %(n)
 Bone marrow 13.3 (110) 21.7 (30) 11.6 (80) 0.002
 Lymph node extirpation 2.8 (23) 9.4 (13) 1.5 (10) <0.001
 Lower endoscopyc 9.9 (82) 8.0 (11) 10.3 (71) 0.397
 Upper endoscopyc 9.6 (79) 5.0 (7) 10.5 (72) 0.049
  1. aCancer or no-cancer within one year after ended diagnostic examination, bFrom date of first visit, cWith or without biopsy. There are less than 5% missing values in every variable except for LDH (5.6%) and Erythrocyte Sedimentation Ratio (48.8%)